专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080081044A1 Compositions and methods for generation of infectious hepatitis C virus in immortalized human hepatocytes 失效
标题翻译：用于在永生化人肝细胞中产生感染性丙型肝炎病毒的组合物和方法
公开(公告)号：US20080081044A1
公开(公告)日：2008-04-03
申请号：US11506161
申请日：2006-08-17
申请人： Ratna Ray , Ranjit Ray , Arnab Basu , Tatsuo Kanda
发明人： Ratna Ray , Ranjit Ray , Arnab Basu , Tatsuo Kanda
IPC分类号： A61K39/29 , C12N5/08 , C12N15/86
CPC分类号： C12N7/00 , A61K2039/525 , C12N2770/24251 , C12Q1/18 , G01N33/5067 , G01N2333/18
摘要： The present invention provides a cell line capable producing infectious hepatitis C virus 1a (HCV 1a) particles in culture. Disclosed are compositions and methods for an HCV 1a (clone H77) transfected immortal human hepatocyte (IHH) capable of generating infectious HCV 1a virus particles in culture. Also disclosed are methods of using the cell line, or HCV 1a virus particles derived from said cell line, to screen for potential therapeutic agents which interfere with HCV 1a virus propagation to treat hepatic disease.
摘要翻译：本发明提供了一种在培养中能够产生感染性丙型肝炎病毒1a（HCV1a）颗粒的细胞系。公开了能够在培养中产生感染性HCV 1a病毒颗粒的HCV 1a（克隆H77）转染的永生人肝细胞（IHH）的组合物和方法。还公开了使用细胞系或源自所述细胞系的HCV 1a病毒颗粒筛选干扰HCV 1a病毒繁殖以治疗肝脏疾病的潜在治疗剂的方法。

2. 发明申请

US20060275838A1 Compositions and methods for inhibiting liver stellate cell growth 审中-公开
标题翻译：抑制肝星状细胞生长的组成和方法
公开(公告)号：US20060275838A1
公开(公告)日：2006-12-07
申请号：US11436384
申请日：2006-05-18
申请人： Ranjit Ray , Ratna Ray , Arnab Basu , Yie-Hwa Chang
发明人： Ranjit Ray , Ratna Ray , Arnab Basu , Yie-Hwa Chang
IPC分类号： G01N33/567 , C07H21/04 , C12P21/06 , C07K14/475 , C12N9/99
CPC分类号： C07K14/4747 , C07K14/4703 , C07K14/4716 , C12P21/06 , G01N2800/085
摘要： The present invention provides compositions and methods for selectively inhibiting the proliferation of stellate cells, which are important for the development of liver fibrosis upon liver injury. The invention describes conditioned media from immortalized hepatocytes as containing a death factor that induces apoptosis of activated liver stellate cells. This pro-apoptotic activity is shown to be associated with the peptide sequence of the actin depolymerizing molecule gelsolin and or fragments thereof. The apoptotic activity is increased upon incubation of immunoglobulins with the stellate death factor.
摘要翻译：本发明提供了选择性抑制星状细胞增殖的组合物和方法，其对于肝损伤时肝纤维化的发展是重要的。本发明描述了来自永生化肝细胞的条件培养基，其含有诱导活化的肝星状细胞凋亡的死亡因子。该促凋亡活性显示与肌动蛋白解聚分子凝溶胶蛋白及其片段的肽序列相关。免疫球蛋白与星状死亡因子的孵育时，凋亡活性增加。

3. 发明申请

US20050266531A1 Compositions and methods for inhibiting liver stellate cell growth 有权
标题翻译：抑制肝星状细胞生长的组成和方法
公开(公告)号：US20050266531A1
公开(公告)日：2005-12-01
申请号：US10888962
申请日：2004-07-09
申请人： Ranjit Ray , Ratna Ray , Arnab Basu , Yie-Hwa Chang
发明人： Ranjit Ray , Ratna Ray , Arnab Basu , Yie-Hwa Chang
IPC分类号： C07H21/04 , C07K14/47 , C07K14/525 , C12N5/08 , C12P21/02
CPC分类号： C07K14/4747
摘要： The present invention provides compositions and methods for selectively inhibiting the proliferation of stellate cells, which are important for the development of liver fibrosis upon liver injury. The invention describes conditioned media from immortalized hepatocytes as containing a death factor that induces apoptosis of activated liver stellate cells. This pro-apoptotic activity is shown to be associated with an 80 kDa protein, which is associated with a fetuin peptide sequence and an albumin peptide sequence.
摘要翻译：本发明提供了选择性抑制星状细胞增殖的组合物和方法，其对于肝损伤时肝纤维化的发展是重要的。本发明描述了来自永生化肝细胞的条件培养基，其含有诱导活化的肝星状细胞凋亡的死亡因子。该促凋亡活性显示与80kDa蛋白质相关，其与胎球蛋白肽序列和白蛋白肽序列相关。

4. 发明授权

US5427782A Intranasal immunization against viral infection using viral glycoprotein subunit vaccine 失效
标题翻译：使用病毒糖蛋白亚基疫苗进行病毒感染的鼻内免疫
公开(公告)号：US5427782A
公开(公告)日：1995-06-27
申请号：US887130
申请日：1992-05-20
申请人： Richard W. Compans , Ranjit Ray
发明人： Richard W. Compans , Ranjit Ray
IPC分类号： A61K39/12 , A61K39/145 , A61K39/155 , A61K39/205 , A61K39/245 , A61K39/00
CPC分类号： A61K39/155 , A61K39/12 , A61K2039/543 , A61K2039/55566 , C12N2760/18634 , Y10S530/806
摘要： Method for immunizing against respiratory vital infection by administering intranasally an immunogenically effective amount of a vital envelope subunit vaccine, preferably comprising a mixture of the vital envelope glycoproteins complexed with a lipid.
摘要翻译：通过鼻内施用免疫有效量的生物包膜亚单位疫苗免疫呼吸性重要感染的方法，优选包含与脂质复合的生命体膜糖蛋白的混合物。

5. 发明申请

US20090148832A1 Compositions and Methods for Generation of Infectious Hepatitis C Virus in Immortalized Human Hepatocytes 审中-公开
标题翻译：在永生化人肝细胞中产生传染性丙型肝炎病毒的组合物和方法
公开(公告)号：US20090148832A1
公开(公告)日：2009-06-11
申请号：US12365523
申请日：2009-02-04
申请人： RATNA RAY , RANJIT RAY , ARNAB BASU , TATSUO KANDA
发明人： RATNA RAY , RANJIT RAY , ARNAB BASU , TATSUO KANDA
IPC分类号： C12Q1/70 , C12N7/00
CPC分类号： C12N7/00 , A61K2039/525 , C12N2770/24251 , C12Q1/18 , G01N33/5067 , G01N2333/18
摘要： The present invention provides a cell line capable producing infectious hepatitis C virus 1a (HCV 1a) particles in culture. Disclosed are compositions and methods for an HCV 1a (clone H77) transfected immortal human hepatocyte (IHH) capable of generating infectious HCV 1a virus particles in culture. Also disclosed are methods of using the cell line, or HCV 1a virus particles derived from said cell line, to screen for potential therapeutic agents which interfere with HCV 1a virus propagation to treat hepatic disease.
摘要翻译：本发明提供了一种在培养中能够产生感染性丙型肝炎病毒1a（HCV1a）颗粒的细胞系。公开了能够在培养中产生感染性HCV 1a病毒颗粒的HCV 1a（克隆H77）转染的永生人肝细胞（IHH）的组合物和方法。还公开了使用细胞系或源自所述细胞系的HCV 1a病毒颗粒筛选干扰HCV 1a病毒繁殖以治疗肝脏疾病的潜在治疗剂的方法。

6. 发明授权

US5843451A Intranasal immunization against viral infection using viral glycoprotein subunit vaccine 失效
标题翻译：使用病毒糖蛋白亚基疫苗进行病毒感染的鼻内免疫
公开(公告)号：US5843451A
公开(公告)日：1998-12-01
申请号：US728735
申请日：1996-10-11
申请人： Richard W. Compans , Ranjit Ray
发明人： Richard W. Compans , Ranjit Ray
IPC分类号： A61K39/12 , A61K39/145 , A61K39/155 , A61K39/205 , A61K39/245 , A61K39/00 , C12N7/00
CPC分类号： A61K39/155 , A61K39/12 , A61K2039/543 , A61K2039/55566 , C12N2760/18634 , Y10S530/806
摘要： Method for immunizing against viral infection by administering intranasally an immunogenically effective amount of a viral envelope subunit vaccine comprising a glycoprotein complexed with a lipid.
摘要翻译：通过鼻内施用免疫有效量的包含与脂质复合的糖蛋白的病毒包膜亚单位疫苗来免疫病毒感染的方法。

7. 发明授权

US4790987A Viral glycoprotein subunit vaccine 失效
标题翻译：病毒糖蛋白亚单位疫苗
公开(公告)号：US4790987A
公开(公告)日：1988-12-13
申请号：US798536
申请日：1985-11-15
申请人： Richard W. Compans , Ranjit Ray
发明人： Richard W. Compans , Ranjit Ray
IPC分类号： C07K14/00 , A61K39/00 , A61K39/12 , C07K1/16 , C07K14/005 , C07K14/115 , C07K14/195 , C07K16/10 , C07K19/00 , C12N5/00 , C12N5/10 , C12N15/00 , C12N15/02 , C12P21/00 , C12P21/08 , C12R1/91 , G01N33/569 , G01N33/577
CPC分类号： C07K14/005 , C07K16/10 , A61K39/00 , C12N2760/18622
摘要： The present invention relates to a vaccine composition useful in preparation of virus-caused disease comprising as its active agent at least one immunogenically effective amount of immunogenic viral envelope glycoprotein complexed with a lipid.
摘要翻译：本发明涉及可用于制备病毒引起的疾病的疫苗组合物，其包含与脂质复合的至少一种免疫原性有效量的免疫原性病毒包膜糖蛋白作为其活性剂。

8. 发明授权

US07504255B2 Compositions and methods for generation of infectious hepatitis C virus in immortalized human hepatocytes 失效
标题翻译：用于在永生化人肝细胞中产生感染性丙型肝炎病毒的组合物和方法
公开(公告)号：US07504255B2
公开(公告)日：2009-03-17
申请号：US11506161
申请日：2006-08-17
申请人： Ratna Ray , Ranjit Ray , Arnab Basu , Tatsuo Kanda
发明人： Ratna Ray , Ranjit Ray , Arnab Basu , Tatsuo Kanda
IPC分类号： C12N5/00 , C12N5/02 , A01N63/00 , A61K39/00 , A61K39/12 , A61K39/29 , A61K39/275
CPC分类号： C12N7/00 , A61K2039/525 , C12N2770/24251 , C12Q1/18 , G01N33/5067 , G01N2333/18
摘要： The present invention provides a cell line capable producing infectious hepatitis C virus 1a (HCV 1a) particles in culture. Disclosed are compositions and methods for an HCV 1a (clone H77) transfected immortal human hepatocyte (IHH) capable of generating infectious HCV 1a virus particles in culture. Also disclosed are methods of using the cell line, or HCV 1a virus particles derived from said cell line, to screen for potential therapeutic agents which interfere with HCV 1a virus propagation to treat hepatic disease.
摘要翻译：本发明提供了一种在培养中能够产生感染性丙型肝炎病毒1a（HCV1a）颗粒的细胞系。公开了能够在培养中产生感染性HCV 1a病毒颗粒的HCV 1a（克隆H77）转染的永生人肝细胞（IHH）的组合物和方法。还公开了使用细胞系或源自所述细胞系的HCV 1a病毒颗粒筛选干扰HCV 1a病毒繁殖以治疗肝脏疾病的潜在治疗剂的方法。

9. 发明授权

US07232893B2 Method of manufacturing a stellate cell death factor 有权
标题翻译：制造星状细胞死亡因子的方法
公开(公告)号：US07232893B2
公开(公告)日：2007-06-19
申请号：US10888962
申请日：2004-07-09
申请人： Ranjit Ray , Ratna Ray , Arnab Basu , Yie-Hwa Chang
发明人： Ranjit Ray , Ratna Ray , Arnab Basu , Yie-Hwa Chang
IPC分类号： C07K1/18 , C12N5/00
CPC分类号： C07K14/4747
摘要： The present invention provides compositions and methods for selectively inhibiting the proliferation of stellate cells, which are important for the development of liver fibrosis upon liver injury. The invention describes conditioned media from immortalized hepatocytes as containing a death factor that induces apoptosis of activated liver stellate cells. This pro-apoptotic activity is shown to be associated with an 80 kDa protein, which is associated with a fetuin peptide sequence and an albumin peptide sequence.
摘要翻译：本发明提供了选择性抑制星状细胞增殖的组合物和方法，其对于肝损伤时肝纤维化的发展是重要的。本发明描述了来自永生化肝细胞的条件培养基，其含有诱导活化的肝星状细胞凋亡的死亡因子。该促凋亡活性显示与80kDa蛋白质相关，其与胎球蛋白肽序列和白蛋白肽序列相关。

10. 发明授权

US6110457A Live attenuated vaccines based on cp45 HPIV-3 strain and method to ensure attenuation in such vaccines 失效
标题翻译：基于cp45 HPIV-3菌株的活减毒疫苗和确保这种疫苗减毒的方法
公开(公告)号：US6110457A
公开(公告)日：2000-08-29
申请号：US987439
申请日：1997-12-09
申请人： Robert B. Belshe , Ranjit Ray
发明人： Robert B. Belshe , Ranjit Ray
IPC分类号： A61K39/00 , A61K39/155 , A61P31/14 , C07K14/115 , A01N63/00 , C12N5/00 , C12N7/00 , C12N15/09
CPC分类号： C07K14/005 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K39/00 , C12N2760/18622 , C12N2760/18634
摘要： The present invention is based upon correlation of two attenuating lesions of the cp45 strain to specific genetic defects in the viral genome of cp45. Specifically, it is now understood that a significant level of attenuation of cp45 giving rise to its temperature-sensitive and cold-adapted phenotypes is directly associated with mutation of the large, or L, gene of cp45 relative to the corresponding gene in the wild-type JS strain. Moreover, it is further understood that a second attenuating lesion exits independent of the temperature-sensitive lesion, and is directly associated with mutation of the hemagglutinin-neuraminidase gene, or HN gene, of cp45 relative to the corresponding gene in the wild-type HPIV-3 (JS) strain. The correlation of these two attenuating lesions of cp45 to specific genes enables several practical applications. It is now possible to create vaccines directed at other wild-type HPIV-3 viruses and, additionally, vaccines directed at target viruses other than HPIV-3 using genetic engineering techniques. For example, the mutated L and/or HN genes of cp45 can be incorporated into the viral genome of a target virus. Alternatively, the genes of the target virus which encode its surface antigens can be incorporated into the viral genome of cp45. Moreover, it is possible to determine whether an HPIV-3 strain or a hybrid virus strain made by the methods disclosed herein is attenuated by confirming the presence or absence of mutations in its L and/or HN genes.
摘要翻译：本发明基于cp45菌株的两个减毒损伤与cp45的病毒基因组中特异性遗传缺陷的相关性。具体来说，现在可以理解，产生其温度敏感性和冷适应表型的cp45的显着水平的衰减与cp45的大的或L的基因相对于野生型的相应基因的突变直接相关， JS型菌株。此外，进一步理解，第二减毒病变独立于温度敏感性病变退出，并且与野生型HPIV中相应基因相关的cp45的血细胞凝集素 - 神经氨酸酶基因或HN基因的突变直接相关 -3（JS）菌株。这两个cp45的减毒病变与特定基因的相关性可以实现几个实际应用。现在可以使用基因工程技术制造针对其他野生型HPIV-3病毒的疫苗，另外还使用针对除HPIV-3之外的靶病毒的疫苗。例如，cp45的突变的L和/或HN基因可以并入目标病毒的病毒基因组中。或者，可以将编码其表面抗原的靶病毒的基因并入cp45的病毒基因组中。此外，可以通过确认其L和/或HN基因中是否存在突变来确定通过本文公开的方法制备的HPIV-3株或杂合病毒株是否被减毒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式